Bailard, Inc. Voyager Therapeutics, Inc. Transaction History

Bailard, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$7.15 - $10.84 $97,955 - $148,508	13,700 New	13,700 $127,000
Q3 2022 Oct 18, 2022	BUY	$5.57 - $7.47 $160,973 - $215,883	28,900 New	28,900 $171,000
Q2 2020 Aug 12, 2020	SELL	$8.05 - $14.21 $1.13 Million - $2 Million	-140,700 Closed	0 $0
Q1 2020 Apr 16, 2020	SELL	$6.8 - $14.66 $183,600 - $395,820	-27,000 Reduced 16.1%	140,700 $1.29 Million
Q4 2019 Jan 31, 2020	BUY	$12.82 - $16.85 $643,564 - $845,870	50,200 Added 42.72%	167,700 $2.34 Million
Q3 2019 Oct 18, 2019	BUY	$16.31 - $28.29 $1.25 Million - $2.16 Million	76,500 Added 186.59%	117,500 $2.02 Million
Q2 2019 Jul 26, 2019	BUY	$19.18 - $27.88 $786,380 - $1.14 Million	41,000 New	41,000 $1.12 Million
Q4 2018 Feb 05, 2019	SELL	$8.59 - $18.05 $188,980 - $397,100	-22,000 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$16.76 - $23.92 $33,520 - $47,840	2,000 Added 10.0%	22,000 $430,000
Q1 2018 May 07, 2018	BUY	$16.16 - $31.31 $96,960 - $187,860	6,000 Added 42.86%	20,000 $376,000
Q4 2017 Feb 08, 2018	BUY	$12.26 - $25.88 $171,640 - $362,320	14,000	14,000 $0

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.